Basket | Login | Register

 
 
 
 

SS1. Primary care and the management of dementia

Detailed Programme, abstracts and presentations

Sube Banerjee, Sandrine Andrieu, Louise Robinson, Jacek Putz

More than 6 million people across Europe currently suffer from Alzheimer’s disease (AD) or a related dementia. As life expectancy increases, the number of people with dementia is also expected to increase, with estimates suggesting that by 2050 in excess of 14 million people in Europe will be living with dementia, representing over 3% of the population.

Estimates also suggest that at least a half of all individuals with AD remain without a formal diagnosis of dementia. Moreover, based on a recent survey conducted in 5 European countries (France, Germany, Italy, Spain and the United Kingdom), for those diagnosed, it can take an average of 48 weeks from the point when symptoms are first noticed to receive a diagnosis of AD, illustrating that a significant time delay to action exists in parts of Europe. It is clear that there is a substantial need for improvements in the identification, diagnosis and referral of patients within the early stages of dementia. Most individuals with cognitive impairments characteristic of these early stages present for help in the primary care setting. As such, ensuring adequate knowledge and experience of dementia management among health care professionals (HCPs) within primary care settings is of upmost importance as we address the increasing future burden of dementia.

During this Pfizer-sponsored symposium, the faculty will address a number of topics related to the role of primary care HCPs in the management of dementia, with a specific focus on (1) identifying those HCPs who should be empowered to help recognise dementia symptoms and to facilitate a diagnosis and/or appropriate referral; (2) determining existing knowledge/service gaps among primary care HCPs within Europe in relation to the current management of patients with dementia, including the interface with specialist secondary care services; (3) exploring the increasingly important future role of primary care HCPs as the numbers of people with dementia continues to increase across the continent; and (4) the potential for appropriate pan-European and/or country-specific systems/policies that will allow primary care doctors and other primary care HCPs to play an effective role in the management of people with dementia.

This special symposium is sponsored by Pfizer.

 

 
 

Last Updated: Friday 02 September 2011

 

 
  • Acknowledgements

    Alzheimer Europe gratefully acknowledges the support of the following sponsors: Fondation Médéric Alzheimer, Fondation Roi Baudouin, Janssen, Lilly, Pfizer, Sanofi and SCA Global Hygiene
  • Fondation Médéric Alzheimer
  • King Baudouin Foundation
  • SCA Global Hygiene
 
 

Options